Method for detecting hydrogen peroxide employing triaryl- and
trihetarylmethane derivatives as redox indicators
    1.
    发明授权
    Method for detecting hydrogen peroxide employing triaryl- and trihetarylmethane derivatives as redox indicators 失效
    使用三芳基和三芳基甲烷衍生物作为氧化还原指示剂检测过氧化氢的方法

    公开(公告)号:US4988616A

    公开(公告)日:1991-01-29

    申请号:US302072

    申请日:1989-01-24

    摘要: A method for detecting hydrogen peroxide wherein a sample is contacted with a peroxidase or a peroxidatively-active substance and a redox indicator of the following ##STR1## in which A and D independently of one another represent phenyl, pyridyl or imidazolyl,G represents O, CH.sub.2 or S,m represents the number zero or one, andX represents O, ##STR2## or --NR.sup.1 --NR.sup.2 -- R.sup.1 and R.sup.2, independently of one another, denote hydrogen, alkyl, cycloalkyl, aryl or aralkyl, or --NR.sup.1 R.sup.2 together represent a pyrrolidine, pyrazoline, piperidine, piperazine or morpholine radical andT denotes hydrogen, hydroxyl, alkyl, aryl, alkoxy, phenoxy, SO.sub.3 H, --COOH or ##STR3## whereby a color change is brought out if hydrogen peroxide is present.

    摘要翻译: 一种检测过氧化氢的方法,其中样品与过氧化物酶或过氧化物活性物质和下列“IMAGE”的氧化还原指示剂接触,其中A和D彼此独立地表示苯基,吡啶基或咪唑基,G表示O, CH2或S,m表示数个零或一个,X表示O,或者-NR1-NR2-R1和R2彼此独立地表示氢,烷基,环烷基,芳基或芳烷基,或-NR1R2一起 代表吡咯烷,吡唑啉,哌啶,哌嗪或吗啉基,T表示氢,羟基,烷基,芳基,烷氧基,苯氧基,SO 3 H,-COOH或,从而如果存在过氧化氢,则出现颜色变化。

    2-hydrazono-4,6-dinitrobenzthiazolones useful to form dyestuffs and as
color formers for detecting peroxide
    5.
    发明授权
    2-hydrazono-4,6-dinitrobenzthiazolones useful to form dyestuffs and as color formers for detecting peroxide 失效
    用于形成染料的2-亚肼基-4,6-二硝基苯并噻唑酮和用作检测过氧化物的成色剂

    公开(公告)号:US4962040A

    公开(公告)日:1990-10-09

    申请号:US392520

    申请日:1989-08-10

    摘要: 2-Hydrazono-4,6-dinitrobenzthiazolones of the formula ##STR1## in which X.sub.1 represents hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -hydroxyalkyl, C.sub.1 -C.sub.4 -sulphoalkyl or C.sub.1 -C.sub.4 -sulphatoalkyl, andX.sub.2 represents hydrogen or --SO.sub.2 X.sub.3, whereX.sub.3 may represent hydrogen, C.sub.1 -C.sub.8 -alkyl or optionally substituted aryl andX.sub.1 also represents a double bond between the cyclic nitrogen atom and the carbon atom 2 according to the formula II below: ##STR2## where X.sub.2 has the meaning specified under the above formula. These hydrazones may be employed in the preparation of azo dyestuffs and as color formers for detecting of biological substances, and in the determination of H.sub.2 O.sub.2.

    摘要翻译: 其中X1表示氢,C1-C4-烷基,C1-C4-羟基烷基,C1-C4-磺基烷基或C1-C4-硫酸烷基的式“IMAGE”的2-肼基-4,6-二硝基苯并噻唑酮,X 2表示氢或 -SO 2 X 3,其中X 3可以表示氢,C 1 -C 8 - 烷基或任选取代的芳基,X 1也表示环状氮原子和根据下式II的碳原子之间的双键:其中X 2具有含义 根据上述公式规定。 这些腙可用于制备偶氮染料和用作检测生物物质的成色剂,并用于测定H 2 O 2。

    Prevention and Treatment of Thromboembolic Disorders
    8.
    发明申请
    Prevention and Treatment of Thromboembolic Disorders 有权
    预防和治疗血栓栓塞性疾病

    公开(公告)号:US20090004265A1

    公开(公告)日:2009-01-01

    申请号:US11883218

    申请日:2006-01-19

    IPC分类号: A61K31/5377 A61K9/20 A61P7/00

    CPC分类号: A61K31/00 A61K31/5377

    摘要: The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.

    摘要翻译: 本发明涉及血液凝固领域,更具体地说,涉及一种治疗血栓栓塞障碍的方法,其通过每日一次,将口服剂型的直接因子Xa抑制剂每天一次给予有需要的患者,其中所述因子Xa抑制剂具有 指示出价或tid管理间隔的血浆浓度半衰期,例如 10小时以内。

    Prevention and treatment of thromboembolic disorders
    10.
    发明授权
    Prevention and treatment of thromboembolic disorders 有权
    预防和治疗血栓栓塞性疾病

    公开(公告)号:US09539218B2

    公开(公告)日:2017-01-10

    申请号:US11883218

    申请日:2006-01-19

    IPC分类号: A61K31/00 A61K31/5377

    CPC分类号: A61K31/00 A61K31/5377

    摘要: The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.

    摘要翻译: 本发明涉及血液凝固领域,更具体地说,涉及一种治疗血栓栓塞障碍的方法,其通过每日一次,将口服剂型的直接因子Xa抑制剂每天一次给予有需要的患者,其中所述因子Xa抑制剂具有 指示出价或tid管理间隔的血浆浓度半衰期,例如 10小时以内。